Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Positron emission tomography for breast cancer deemed cost-effective in Canada
February 14th, 2006
Use of positron emission tomography (PET) for staging breast cancer was deemed cost-effective in Canada. "In this study, we used quantitative decision tree modeling to assess the cost-effectiveness of a PET-based management scenario for breast cancer in Canada. Procedures: Two patient management scenarios were compared (with and without PET)," investigators in Canada reported. "A metaanalysis of studies for the accuracy of PET in staging breast cancer was conducted. Life expectancies were calculated. Management costs were determined from previous cost-effective analyses, management costs from our institutions, and recently published Canadian cost...
Source: Cancer Weekly (2006-02-14)
|
